-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, April 9th
Chairman Pien Tze Huang resigns
On April 8, Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
issued an announcement on the retirement and resignation of the chairman.
The announcement stated that Liu Jianshun had specifically applied to the board of directors for early retirement due to personal health reasons, and resigned from the company's directors, chairman of the board, and members of special committees under the board of directors.
, Ltd.
issued an announcement on the retirement and resignation of the chairman.
The announcement stated that Liu Jianshun had specifically applied to the board of directors for early retirement due to personal health reasons, and resigned from the company's directors, chairman of the board, and members of special committees under the board of directors.
Liu Jianshun's resignation report took effect from the day it was delivered to the company's board of directors.
After resignation, Liu Jianshun no longer holds any position in the company.
After resignation, Liu Jianshun no longer holds any position in the company.
Public information shows that Liu Jianshun has served as a member of the Organization Section of the Organization Department of the Zhangzhou Municipal Party Committee, a deputy section chief of the Party and Mass Section, a cadre of the organization department, an organizer of the municipal party committee, the section chief of the Organization Department and the deputy director of the Beijing Office of the Zhangzhou Municipal Government.
Since March 2014, he has been the chairman of Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
He has won the honorary titles of National Outstanding Entrepreneur and 40 Fujian Most Influential Entrepreneurs in the 40 years of reform and opening up.
Since March 2014, he has been the chairman of Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
He has won the honorary titles of National Outstanding Entrepreneur and 40 Fujian Most Influential Entrepreneurs in the 40 years of reform and opening up.
According to the announcement, since Liu Jianshun joined the company in 2014, he has led the company to implement the "one core and two wings" big health industry development strategy to promote the company's high-quality development in an all-round way.
The company's operating efficiency has been improving year by year, the industrial layout has been improved, and the brand influence has continued to improve.
The company's operating efficiency has been improving year by year, the industrial layout has been improved, and the brand influence has continued to improve.
The announcement showed that the board of directors appointed Pan Jie as the chairman of the company.
It is understood that Pan Jie successively served as the manager of the Import and Export Department of Zhangzhou Pharmaceutical Factory, the deputy general manager of Zhangzhou Pien Tze Huang Group Company, and the director, deputy general manager and general manager of Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
Since 2014, he has served as the chairman of Zhangzhou Jiulongjiang Group Co.
, Ltd.
; since 2017, he has also served as a director of Fujian Fuhua Gulei Petrochemical Co.
, Ltd.
; since October 2017, he has also served as a director of Fujian Fuhaichuang Petrochemical Co.
, Ltd.
It is understood that Pan Jie successively served as the manager of the Import and Export Department of Zhangzhou Pharmaceutical Factory, the deputy general manager of Zhangzhou Pien Tze Huang Group Company, and the director, deputy general manager and general manager of Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
Since 2014, he has served as the chairman of Zhangzhou Jiulongjiang Group Co.
, Ltd.
; since 2017, he has also served as a director of Fujian Fuhua Gulei Petrochemical Co.
, Ltd.
; since October 2017, he has also served as a director of Fujian Fuhaichuang Petrochemical Co.
, Ltd.
Performance continues to grow
In recent years, the continuous growth of Pien Tze Huang's performance has attracted the attention of the industry.
A few days ago, the company released the 2020 annual performance bulletin.
According to preliminary calculations, the company will achieve operating income of 6.
507 billion yuan in 2020, an increase of 13.
72% year-on-year; operating profit of 1.
972 billion yuan, an increase of 20.
40% year-on-year; net profit attributable to the parent company of 1.
667 billion yuan, year-on-year An increase of 21.
27%, and a net profit of 1.
613 billion yuan deducted from the parent, a year-on-year increase of 19.
11%.
A few days ago, the company released the 2020 annual performance bulletin.
According to preliminary calculations, the company will achieve operating income of 6.
507 billion yuan in 2020, an increase of 13.
72% year-on-year; operating profit of 1.
972 billion yuan, an increase of 20.
40% year-on-year; net profit attributable to the parent company of 1.
667 billion yuan, year-on-year An increase of 21.
27%, and a net profit of 1.
613 billion yuan deducted from the parent, a year-on-year increase of 19.
11%.
The announcement revealed that the main reason for such growth was the increase in sales of the company's core product Pien Tze Huang series products and its holding subsidiary Fujian Pien Tze Huang Cosmetics Co.
, Ltd.
(consolidated) after strengthening market planning and expanding sales channels .
, Ltd.
(consolidated) after strengthening market planning and expanding sales channels .
The company's core product, Pien Tze Huang, is a nationally certified first-level protected traditional Chinese medicine, and is also a national top-secret formula.
It has a permanent confidentiality period and has the right to use the scarce raw material musk.
These have laid the foundation for its price increase and continue to drive the company's turnover.
According to incomplete statistics, from 2004 to 2020, the domestic retail price of Pien Tze Huang has increased 9 times, and the price of a single piece (3g) has increased from 325 yuan to 590 yuan, an increase of 81%.
The export retail price has been raised 10 times in total, from 14.
5 US dollars per ingot to 51.
8 US dollars per ingot, an increase of 257%.
It has a permanent confidentiality period and has the right to use the scarce raw material musk.
These have laid the foundation for its price increase and continue to drive the company's turnover.
According to incomplete statistics, from 2004 to 2020, the domestic retail price of Pien Tze Huang has increased 9 times, and the price of a single piece (3g) has increased from 325 yuan to 590 yuan, an increase of 81%.
The export retail price has been raised 10 times in total, from 14.
5 US dollars per ingot to 51.
8 US dollars per ingot, an increase of 257%.
Despite this, the volume and price of Pien Tze Huang continued to rise, and the price increase still did not reach the ceiling.
At the beginning of 2020, the company announced that the terminal retail price of Pien Tze Huang tablets was raised from 530 yuan to 590 yuan, and the enthusiasm of channel merchants to destock was greatly increased.
At the end of 2020, some retail terminals still experienced product shortages.
At the beginning of 2020, the company announced that the terminal retail price of Pien Tze Huang tablets was raised from 530 yuan to 590 yuan, and the enthusiasm of channel merchants to destock was greatly increased.
At the end of 2020, some retail terminals still experienced product shortages.
However, the market believes that in the process of digesting the price increase dividend, Pien Tze Huang is facing a serious problem that is too dependent on a single product.
In response to this problem, Liu Jianshun, the former chairman of 2014, proposed a "one core and two wings" strategy for healthy development: to maintain the core advantage of leading traditional Chinese medicine manufacturers as "one core", and to take the development of health food and daily chemical products as "one core".
"Two wings", supplemented by the circulation of medicines .
"Two wings", supplemented by the circulation of medicines .
Pharmaceutical companies have crossed borders
In the era of great health, seeking diversified development, the cross-border health care products and daily chemical industries are nothing new in the Chinese medicine industry.
Yunnan Baiyao, an old traditional Chinese medicine store, frankly stated that many of the company's core products have a high market share, and there is not much market space for traditional products to maintain sustained and rapid growth, and the need for transformation and development is very urgent.
In fact, Yunnan Baiyao’s transformation has been successful.
Its toothpaste business has revenue of over 4.
5 billion yuan in 2019.
The revenue of the toothpaste-based health product business unit exceeds the pharmaceutical business unit, and the toothpaste market share is the first in the country (20.
1%).
Shampoo care , The field of skin care is also expanding.
Its toothpaste business has revenue of over 4.
5 billion yuan in 2019.
The revenue of the toothpaste-based health product business unit exceeds the pharmaceutical business unit, and the toothpaste market share is the first in the country (20.
1%).
Shampoo care , The field of skin care is also expanding.
But not every Chinese medicine company can be as lucky as Yunnan Baiyao.
Although there are many cross-border pharmaceutical companies, professional brand influence is still greater, and compared with companies that specialize in related industries, pharmaceutical companies have weaker channels.
Although there are many cross-border pharmaceutical companies, professional brand influence is still greater, and compared with companies that specialize in related industries, pharmaceutical companies have weaker channels.
In 2009, Ma Yinglong launched the Eight Treasure Eye Cream and entered the cosmetics industry.
Since then, the "Ma Yinglong Lipstick" launched immediately became popular and appeared on Weibo's hot search.
But judging from the 2020 annual report, the cosmetics sector has not brought much benefit to the company.
Revenue in 2020 was 365 million, down 35.
56% from the same period last year, and gross profit margin was 49.
1%, down 10.
73% from the same period last year.
Since then, the "Ma Yinglong Lipstick" launched immediately became popular and appeared on Weibo's hot search.
But judging from the 2020 annual report, the cosmetics sector has not brought much benefit to the company.
Revenue in 2020 was 365 million, down 35.
56% from the same period last year, and gross profit margin was 49.
1%, down 10.
73% from the same period last year.
On the one hand, due to the fierce market competition, Ma Yinglong’s marketing strategy and product innovation capabilities are not strong.
On the other hand, Ma Yinglong is well-known as a hemorrhoid medicine, which lacks synergy with daily consumer products, and the contrast is too large.
The current results are still consumption.
Ma Yinglong gained his own brand value.
On the other hand, Ma Yinglong is well-known as a hemorrhoid medicine, which lacks synergy with daily consumer products, and the contrast is too large.
The current results are still consumption.
Ma Yinglong gained his own brand value.
Pien Tze Huang’s daily chemical segment focuses on two series of products, the “Pien Tze Huang” high-end brand and the “Queen” popular brand.
Although they have provided an important impetus to the company’s performance growth, the pharmaceutical and pharmaceutical industry is still the company’s main source of revenue.
The cosmetics business is in the company.
The revenue accounted for about 10%.
Although they have provided an important impetus to the company’s performance growth, the pharmaceutical and pharmaceutical industry is still the company’s main source of revenue.
The cosmetics business is in the company.
The revenue accounted for about 10%.
For pharmaceutical companies, R&D strength is the embodiment of their core competitiveness, and Pien Tze Huang’s R&D investment is obviously insufficient.
Pien Tze Huang's research and development expenses in 2018, 2019 and the third quarter of 2020 were 101 million yuan, 119 million yuan, and 93 million yuan, accounting for 2.
12%, 2.
08%, and 1.
83% of revenue, respectively.
This is essentially a common problem faced by the Chinese medicine industry, and both R&D investment and innovation capabilities need to be improved.
Pien Tze Huang's research and development expenses in 2018, 2019 and the third quarter of 2020 were 101 million yuan, 119 million yuan, and 93 million yuan, accounting for 2.
12%, 2.
08%, and 1.
83% of revenue, respectively.
This is essentially a common problem faced by the Chinese medicine industry, and both R&D investment and innovation capabilities need to be improved.
Previously, a senior executive of a pharmaceutical company revealed: “Now the barriers to making medicines are getting higher and higher, the investment in new product research and development is huge, and the cycle is very long, which discourages some weak companies.
In contrast, the risks of cosmetics investment and failure are Much lower.
"
In contrast, the risks of cosmetics investment and failure are Much lower.
"
With the continuous deepening of medical reform, the advancement of policies such as hospital channel restriction, supplementary restriction, mass procurement, medical insurance payment method reform, and two-invoice system, the pharmaceutical industry environment has undergone drastic changes, and drug companies have brought considerable operating pressure.
However, whether the crossover of pharmaceutical companies can really become the driving force for the growth of pharmaceutical companies' performance remains to be verified by time.
However, whether the crossover of pharmaceutical companies can really become the driving force for the growth of pharmaceutical companies' performance remains to be verified by time.
Medical News, April 9th
Chairman Pien Tze Huang resigns
On April 8, Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
issued an announcement on the retirement and resignation of the chairman.
The announcement stated that Liu Jianshun had specifically applied to the board of directors for early retirement due to personal health reasons, and resigned from the company's directors, chairman of the board, and members of special committees under the board of directors.
, Ltd.
issued an announcement on the retirement and resignation of the chairman.
The announcement stated that Liu Jianshun had specifically applied to the board of directors for early retirement due to personal health reasons, and resigned from the company's directors, chairman of the board, and members of special committees under the board of directors.
Liu Jianshun's resignation report took effect from the day it was delivered to the company's board of directors.
After resignation, Liu Jianshun no longer holds any position in the company.
After resignation, Liu Jianshun no longer holds any position in the company.
Public information shows that Liu Jianshun has served as a member of the Organization Section of the Organization Department of the Zhangzhou Municipal Party Committee, a deputy section chief of the Party and Mass Section, a cadre of the organization department, an organizer of the municipal party committee, the section chief of the Organization Department and the deputy director of the Beijing Office of the Zhangzhou Municipal Government.
Since March 2014, he has been the chairman of Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
He has won the honorary titles of National Outstanding Entrepreneur and 40 Fujian Most Influential Entrepreneurs in the 40 years of reform and opening up.
Since March 2014, he has been the chairman of Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
He has won the honorary titles of National Outstanding Entrepreneur and 40 Fujian Most Influential Entrepreneurs in the 40 years of reform and opening up.
According to the announcement, since Liu Jianshun joined the company in 2014, he has led the company to implement the "one core and two wings" big health industry development strategy to promote the company's high-quality development in an all-round way.
The company's operating efficiency has been improving year by year, the industrial layout has been improved, and the brand influence has continued to improve.
The company's operating efficiency has been improving year by year, the industrial layout has been improved, and the brand influence has continued to improve.
The announcement showed that the board of directors appointed Pan Jie as the chairman of the company.
It is understood that Pan Jie successively served as the manager of the Import and Export Department of Zhangzhou Pharmaceutical Factory, the deputy general manager of Zhangzhou Pien Tze Huang Group Company, and the director, deputy general manager and general manager of Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
Since 2014, he has served as the chairman of Zhangzhou Jiulongjiang Group Co.
, Ltd.
; since 2017, he has also served as a director of Fujian Fuhua Gulei Petrochemical Co.
, Ltd.
; since October 2017, he has also served as a director of Fujian Fuhaichuang Petrochemical Co.
, Ltd.
It is understood that Pan Jie successively served as the manager of the Import and Export Department of Zhangzhou Pharmaceutical Factory, the deputy general manager of Zhangzhou Pien Tze Huang Group Company, and the director, deputy general manager and general manager of Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
Since 2014, he has served as the chairman of Zhangzhou Jiulongjiang Group Co.
, Ltd.
; since 2017, he has also served as a director of Fujian Fuhua Gulei Petrochemical Co.
, Ltd.
; since October 2017, he has also served as a director of Fujian Fuhaichuang Petrochemical Co.
, Ltd.
Performance continues to grow
In recent years, the continuous growth of Pien Tze Huang's performance has attracted the attention of the industry.
A few days ago, the company released the 2020 annual performance bulletin.
According to preliminary calculations, the company will achieve operating income of 6.
507 billion yuan in 2020, an increase of 13.
72% year-on-year; operating profit of 1.
972 billion yuan, an increase of 20.
40% year-on-year; net profit attributable to the parent company of 1.
667 billion yuan, year-on-year An increase of 21.
27%, and a net profit of 1.
613 billion yuan deducted from the parent, a year-on-year increase of 19.
11%.
A few days ago, the company released the 2020 annual performance bulletin.
According to preliminary calculations, the company will achieve operating income of 6.
507 billion yuan in 2020, an increase of 13.
72% year-on-year; operating profit of 1.
972 billion yuan, an increase of 20.
40% year-on-year; net profit attributable to the parent company of 1.
667 billion yuan, year-on-year An increase of 21.
27%, and a net profit of 1.
613 billion yuan deducted from the parent, a year-on-year increase of 19.
11%.
The announcement revealed that the main reason for such growth was the increase in sales of the company's core product Pien Tze Huang series products and its holding subsidiary Fujian Pien Tze Huang Cosmetics Co.
, Ltd.
(consolidated) after strengthening market planning and expanding sales channels .
, Ltd.
(consolidated) after strengthening market planning and expanding sales channels .
The company's core product, Pien Tze Huang, is a nationally certified first-level protected traditional Chinese medicine, and is also a national top-secret formula.
It has a permanent confidentiality period and has the right to use the scarce raw material musk.
These have laid the foundation for its price increase and continue to drive the company's turnover.
According to incomplete statistics, from 2004 to 2020, the domestic retail price of Pien Tze Huang has increased 9 times, and the price of a single piece (3g) has increased from 325 yuan to 590 yuan, an increase of 81%.
The export retail price has been raised 10 times in total, from 14.
5 US dollars per ingot to 51.
8 US dollars per ingot, an increase of 257%.
It has a permanent confidentiality period and has the right to use the scarce raw material musk.
These have laid the foundation for its price increase and continue to drive the company's turnover.
According to incomplete statistics, from 2004 to 2020, the domestic retail price of Pien Tze Huang has increased 9 times, and the price of a single piece (3g) has increased from 325 yuan to 590 yuan, an increase of 81%.
The export retail price has been raised 10 times in total, from 14.
5 US dollars per ingot to 51.
8 US dollars per ingot, an increase of 257%.
Despite this, the volume and price of Pien Tze Huang continued to rise, and the price increase still did not reach the ceiling.
At the beginning of 2020, the company announced that the terminal retail price of Pien Tze Huang tablets was raised from 530 yuan to 590 yuan, and the enthusiasm of channel merchants to destock was greatly increased.
At the end of 2020, some retail terminals still experienced product shortages.
At the beginning of 2020, the company announced that the terminal retail price of Pien Tze Huang tablets was raised from 530 yuan to 590 yuan, and the enthusiasm of channel merchants to destock was greatly increased.
At the end of 2020, some retail terminals still experienced product shortages.
However, the market believes that in the process of digesting the price increase dividend, Pien Tze Huang is facing a serious problem that is too dependent on a single product.
In response to this problem, Liu Jianshun, the former chairman of 2014, proposed a "one core and two wings" strategy for healthy development: to maintain the core advantage of leading traditional Chinese medicine manufacturers as "one core", and to take the development of health food and daily chemical products as "one core".
"Two wings", supplemented by the circulation of medicines .
"Two wings", supplemented by the circulation of medicines .
Pharmaceutical companies have crossed borders
In the era of great health, seeking diversified development, the cross-border health care products and daily chemical industries are nothing new in the Chinese medicine industry.
Yunnan Baiyao, an old traditional Chinese medicine store, frankly stated that many of the company's core products have a high market share, and there is not much market space for traditional products to maintain sustained and rapid growth, and the need for transformation and development is very urgent.
In fact, Yunnan Baiyao’s transformation has been successful.
Its toothpaste business has revenue of over 4.
5 billion yuan in 2019.
The revenue of the toothpaste-based health product business unit exceeds the pharmaceutical business unit, and the toothpaste market share is the first in the country (20.
1%).
Shampoo care , The field of skin care is also expanding.
Its toothpaste business has revenue of over 4.
5 billion yuan in 2019.
The revenue of the toothpaste-based health product business unit exceeds the pharmaceutical business unit, and the toothpaste market share is the first in the country (20.
1%).
Shampoo care , The field of skin care is also expanding.
But not every Chinese medicine company can be as lucky as Yunnan Baiyao.
Although there are many cross-border pharmaceutical companies, professional brand influence is still greater, and compared with companies that specialize in related industries, pharmaceutical companies have weaker channels.
Although there are many cross-border pharmaceutical companies, professional brand influence is still greater, and compared with companies that specialize in related industries, pharmaceutical companies have weaker channels.
In 2009, Ma Yinglong launched the Eight Treasure Eye Cream and entered the cosmetics industry.
Since then, the "Ma Yinglong Lipstick" launched immediately became popular and appeared on Weibo's hot search.
But judging from the 2020 annual report, the cosmetics sector has not brought much benefit to the company.
Revenue in 2020 was 365 million, down 35.
56% from the same period last year, and gross profit margin was 49.
1%, down 10.
73% from the same period last year.
Since then, the "Ma Yinglong Lipstick" launched immediately became popular and appeared on Weibo's hot search.
But judging from the 2020 annual report, the cosmetics sector has not brought much benefit to the company.
Revenue in 2020 was 365 million, down 35.
56% from the same period last year, and gross profit margin was 49.
1%, down 10.
73% from the same period last year.
On the one hand, due to the fierce market competition, Ma Yinglong’s marketing strategy and product innovation capabilities are not strong.
On the other hand, Ma Yinglong is well-known as a hemorrhoid medicine, which lacks synergy with daily consumer products, and the contrast is too large.
The current results are still consumption.
Ma Yinglong gained his own brand value.
On the other hand, Ma Yinglong is well-known as a hemorrhoid medicine, which lacks synergy with daily consumer products, and the contrast is too large.
The current results are still consumption.
Ma Yinglong gained his own brand value.
Pien Tze Huang’s daily chemical segment focuses on two series of products, the “Pien Tze Huang” high-end brand and the “Queen” popular brand.
Although they have provided an important impetus to the company’s performance growth, the pharmaceutical and pharmaceutical industry is still the company’s main source of revenue.
The cosmetics business is in the company.
The revenue accounted for about 10%.
Although they have provided an important impetus to the company’s performance growth, the pharmaceutical and pharmaceutical industry is still the company’s main source of revenue.
The cosmetics business is in the company.
The revenue accounted for about 10%.
For pharmaceutical companies, R&D strength is the embodiment of their core competitiveness, and Pien Tze Huang’s R&D investment is obviously insufficient.
Pien Tze Huang's research and development expenses in 2018, 2019 and the third quarter of 2020 were 101 million yuan, 119 million yuan, and 93 million yuan, accounting for 2.
12%, 2.
08%, and 1.
83% of revenue, respectively.
This is essentially a common problem faced by the Chinese medicine industry, and both R&D investment and innovation capabilities need to be improved.
Pien Tze Huang's research and development expenses in 2018, 2019 and the third quarter of 2020 were 101 million yuan, 119 million yuan, and 93 million yuan, accounting for 2.
12%, 2.
08%, and 1.
83% of revenue, respectively.
This is essentially a common problem faced by the Chinese medicine industry, and both R&D investment and innovation capabilities need to be improved.
Previously, a senior executive of a pharmaceutical company revealed: “Now the barriers to making medicines are getting higher and higher, the investment in new product research and development is huge, and the cycle is very long, which discourages some weak companies.
In contrast, the risks of cosmetics investment and failure are Much lower.
"
In contrast, the risks of cosmetics investment and failure are Much lower.
"
With the continuous deepening of medical reform, the advancement of policies such as hospital channel restriction, supplementary restriction, mass procurement, medical insurance payment method reform, and two-invoice system, the pharmaceutical industry environment has undergone drastic changes, and drug companies have brought considerable operating pressure.
However, whether the crossover of pharmaceutical companies can really become the driving force for the growth of pharmaceutical companies' performance remains to be verified by time.
However, whether the crossover of pharmaceutical companies can really become the driving force for the growth of pharmaceutical companies' performance remains to be verified by time.
Medical News, April 9th
Chairman Pien Tze Huang resigns
Chairman Pien Tze Huang resigns On April 8, Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
issued an announcement on the retirement and resignation of the chairman.
The announcement stated that Liu Jianshun had specifically applied to the board of directors for early retirement due to personal health reasons, and resigned from the company's directors, chairman of the board, and members of special committees under the board of directors.
, Ltd.
issued an announcement on the retirement and resignation of the chairman.
The announcement stated that Liu Jianshun had specifically applied to the board of directors for early retirement due to personal health reasons, and resigned from the company's directors, chairman of the board, and members of special committees under the board of directors.
Liu Jianshun's resignation report took effect from the day it was delivered to the company's board of directors.
After resignation, Liu Jianshun no longer holds any position in the company.
After resignation, Liu Jianshun no longer holds any position in the company.
Public information shows that Liu Jianshun has served as a member of the Organization Section of the Organization Department of the Zhangzhou Municipal Party Committee, a deputy section chief of the Party and Mass Section, a cadre of the organization department, an organizer of the municipal party committee, the section chief of the Organization Department and the deputy director of the Beijing Office of the Zhangzhou Municipal Government.
Since March 2014, he has been the chairman of Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
He has won the honorary titles of National Outstanding Entrepreneur and 40 Fujian Most Influential Entrepreneurs in the 40 years of reform and opening up.
Since March 2014, he has been the chairman of Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
He has won the honorary titles of National Outstanding Entrepreneur and 40 Fujian Most Influential Entrepreneurs in the 40 years of reform and opening up.
According to the announcement, since Liu Jianshun joined the company in 2014, he has led the company to implement the "one core and two wings" big health industry development strategy to promote the company's high-quality development in an all-round way.
The company's operating efficiency has been improving year by year, the industrial layout has been improved, and the brand influence has continued to improve.
The company's operating efficiency has been improving year by year, the industrial layout has been improved, and the brand influence has continued to improve.
The announcement showed that the board of directors appointed Pan Jie as the chairman of the company.
It is understood that Pan Jie successively served as the manager of the Import and Export Department of Zhangzhou Pharmaceutical Factory, the deputy general manager of Zhangzhou Pien Tze Huang Group Company, and the director, deputy general manager and general manager of Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
Since 2014, he has served as the chairman of Zhangzhou Jiulongjiang Group Co.
, Ltd.
; since 2017, he has also served as a director of Fujian Fuhua Gulei Petrochemical Co.
, Ltd.
; since October 2017, he has also served as a director of Fujian Fuhaichuang Petrochemical Co.
, Ltd.
It is understood that Pan Jie successively served as the manager of the Import and Export Department of Zhangzhou Pharmaceutical Factory, the deputy general manager of Zhangzhou Pien Tze Huang Group Company, and the director, deputy general manager and general manager of Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
Since 2014, he has served as the chairman of Zhangzhou Jiulongjiang Group Co.
, Ltd.
; since 2017, he has also served as a director of Fujian Fuhua Gulei Petrochemical Co.
, Ltd.
; since October 2017, he has also served as a director of Fujian Fuhaichuang Petrochemical Co.
, Ltd.
Performance continues to grow
Performance continues to grow In recent years, the continuous growth of Pien Tze Huang's performance has attracted the attention of the industry.
A few days ago, the company released the 2020 annual performance bulletin.
According to preliminary calculations, the company will achieve operating income of 6.
507 billion yuan in 2020, an increase of 13.
72% year-on-year; operating profit of 1.
972 billion yuan, an increase of 20.
40% year-on-year; net profit attributable to the parent company of 1.
667 billion yuan, year-on-year An increase of 21.
27%, and a net profit of 1.
613 billion yuan deducted from the parent, a year-on-year increase of 19.
11%.
A few days ago, the company released the 2020 annual performance bulletin.
According to preliminary calculations, the company will achieve operating income of 6.
507 billion yuan in 2020, an increase of 13.
72% year-on-year; operating profit of 1.
972 billion yuan, an increase of 20.
40% year-on-year; net profit attributable to the parent company of 1.
667 billion yuan, year-on-year An increase of 21.
27%, and a net profit of 1.
613 billion yuan deducted from the parent, a year-on-year increase of 19.
11%.
The announcement revealed that the main reason for such growth was the increase in sales of the company's core product Pien Tze Huang series products and its holding subsidiary Fujian Pien Tze Huang Cosmetics Co.
, Ltd.
(consolidated) after strengthening market planning and expanding sales channels .
Cosmetics, cosmetics, cosmetics, Ltd.
(consolidated) after strengthening market planning and expanding sales channels .
The company's core product, Pien Tze Huang, is a nationally certified first-level protected traditional Chinese medicine, and is also a national top-secret formula.
It has a permanent confidentiality period and has the right to use the scarce raw material musk.
These have laid the foundation for its price increase and continue to drive the company's turnover.
According to incomplete statistics, from 2004 to 2020, the domestic retail price of Pien Tze Huang has increased 9 times, and the price of a single piece (3g) has increased from 325 yuan to 590 yuan, an increase of 81%.
The export retail price has been raised 10 times in total, from 14.
5 US dollars per ingot to 51.
8 US dollars per ingot, an increase of 257%.
It has a permanent confidentiality period and has the right to use the scarce raw material musk.
These have laid the foundation for its price increase and continue to drive the company's turnover.
According to incomplete statistics, from 2004 to 2020, the domestic retail price of Pien Tze Huang has increased 9 times, and the price of a single piece (3g) has increased from 325 yuan to 590 yuan, an increase of 81%.
The export retail price has been raised 10 times in total, from 14.
5 US dollars per ingot to 51.
8 US dollars per ingot, an increase of 257%.
Despite this, the volume and price of Pien Tze Huang continued to rise, and the price increase still did not reach the ceiling.
At the beginning of 2020, the company announced that the terminal retail price of Pien Tze Huang tablets was raised from 530 yuan to 590 yuan, and the enthusiasm of channel merchants to destock was greatly increased.
At the end of 2020, some retail terminals still experienced product shortages.
At the beginning of 2020, the company announced that the terminal retail price of Pien Tze Huang tablets was raised from 530 yuan to 590 yuan, and the enthusiasm of channel merchants to destock was greatly increased.
At the end of 2020, some retail terminals still experienced product shortages.
However, the market believes that in the process of digesting the price increase dividend, Pien Tze Huang is facing a serious problem that is too dependent on a single product.
In response to this problem, Liu Jianshun, the former chairman of 2014, proposed a "one core and two wings" strategy for healthy development: to maintain the core advantage of leading traditional Chinese medicine manufacturers as "one core", and to take the development of health food and daily chemical products as "one core".
"Two wings", supplemented by the circulation of medicines .
Health food, health food, health food, medicine, medicine, medicine"Two wings", supplemented by the circulation of medicines .
Pharmaceutical companies have crossed borders
Pharmaceutical companies have crossed borders In the era of great health, seeking diversified development, the cross-border health care products and daily chemical industries are nothing new in the Chinese medicine industry.
Health care products health products Yunnan Baiyao, an old traditional Chinese medicine store, frankly stated that many of the company's core products have a high market share, and there is not much market space for traditional products to maintain sustained and rapid growth, and the need for transformation and development is very urgent.
In fact, Yunnan Baiyao’s transformation has been successful.
Its toothpaste business has revenue of over 4.
5 billion yuan in 2019.
The revenue of the toothpaste-based health product business unit exceeds the pharmaceutical business unit, and the toothpaste market share is the first in the country (20.
1%).
Shampoo care , The field of skin care is also expanding.
Its toothpaste business has revenue of over 4.
5 billion yuan in 2019.
The revenue of the toothpaste-based health product business unit exceeds the pharmaceutical business unit, and the toothpaste market share is the first in the country (20.
1%).
Shampoo care , The field of skin care is also expanding.
But not every Chinese medicine company can be as lucky as Yunnan Baiyao.
Although there are many cross-border pharmaceutical companies, professional brand influence is still greater, and compared with companies that specialize in related industries, pharmaceutical companies have weaker channels.
Although there are many cross-border pharmaceutical companies, professional brand influence is still greater, and compared with companies that specialize in related industries, pharmaceutical companies have weaker channels.
In 2009, Ma Yinglong launched the Eight Treasure Eye Cream and entered the cosmetics industry.
Since then, the "Ma Yinglong Lipstick" launched immediately became popular and appeared on Weibo's hot search.
But judging from the 2020 annual report, the cosmetics sector has not brought much benefit to the company.
Revenue in 2020 was 365 million, down 35.
56% from the same period last year, and gross profit margin was 49.
1%, down 10.
73% from the same period last year.
Since then, the "Ma Yinglong Lipstick" launched immediately became popular and appeared on Weibo's hot search.
But judging from the 2020 annual report, the cosmetics sector has not brought much benefit to the company.
Revenue in 2020 was 365 million, down 35.
56% from the same period last year, and gross profit margin was 49.
1%, down 10.
73% from the same period last year.
On the one hand, due to the fierce market competition, Ma Yinglong’s marketing strategy and product innovation capabilities are not strong.
On the other hand, Ma Yinglong is well-known as a hemorrhoid medicine, which lacks synergy with daily consumer products, and the contrast is too large.
The current results are still consumption.
Ma Yinglong gained his own brand value.
On the other hand, Ma Yinglong is well-known as a hemorrhoid medicine, which lacks synergy with daily consumer products, and the contrast is too large.
The current results are still consumption.
Ma Yinglong gained his own brand value.
Pien Tze Huang’s daily chemical segment focuses on two series of products, the “Pien Tze Huang” high-end brand and the “Queen” popular brand.
Although they have provided an important impetus to the company’s performance growth, the pharmaceutical and pharmaceutical industry is still the company’s main source of revenue.
The cosmetics business is in the company.
The revenue accounted for about 10%.
Medicine Medicine MedicineAlthough they have provided an important impetus to the company’s performance growth, the pharmaceutical and pharmaceutical industry is still the company’s main source of revenue.
The cosmetics business is in the company.
The revenue accounted for about 10%.
For pharmaceutical companies, R&D strength is the embodiment of their core competitiveness, and Pien Tze Huang’s R&D investment is obviously insufficient.
Pien Tze Huang's research and development expenses in 2018, 2019 and the third quarter of 2020 were 101 million yuan, 119 million yuan, and 93 million yuan, accounting for 2.
12%, 2.
08%, and 1.
83% of revenue, respectively.
This is essentially a common problem faced by the Chinese medicine industry, and both R&D investment and innovation capabilities need to be improved.
Pien Tze Huang's research and development expenses in 2018, 2019 and the third quarter of 2020 were 101 million yuan, 119 million yuan, and 93 million yuan, accounting for 2.
12%, 2.
08%, and 1.
83% of revenue, respectively.
This is essentially a common problem faced by the Chinese medicine industry, and both R&D investment and innovation capabilities need to be improved.
Previously, a senior executive of a pharmaceutical company revealed: “Now the barriers to making medicines are getting higher and higher, the investment in new product research and development is huge, and the cycle is very long, which discourages some weak companies.
In contrast, the risks of cosmetics investment and failure are Much lower.
"
In contrast, the risks of cosmetics investment and failure are Much lower.
"
With the continuous deepening of medical reform, the advancement of policies such as hospital channel restriction, supplementary restriction, mass procurement, medical insurance payment method reform, and two-invoice system, the pharmaceutical industry environment has undergone drastic changes, and drug companies have brought considerable operating pressure.
However, whether the crossover of pharmaceutical companies can really become the driving force for the growth of pharmaceutical companies' performance remains to be verified by time.
However, whether the crossover of pharmaceutical companies can really become the driving force for the growth of pharmaceutical companies' performance remains to be verified by time.
